Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Dyslipidemia

  Free Subscription


28.06.2021

1 Am J Epidemiol
32 Atherosclerosis
3 Curr Opin Lipidol
2 Metabolism
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Epidemiol

  1. CHANG CY, Muo CH, Yeh YC, Lu CY, et al
    Associations of Endometriosis and Hormone Therapy With Risk of Hyperlipidemia.
    Am J Epidemiol. 2021;190:277-287.
    PubMed         Abstract available


    Atherosclerosis

  2. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed         Abstract available

  3. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed         Abstract available

  4. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed         Abstract available

  5. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed         Abstract available

  6. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed         Abstract available

  7. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    PubMed         Abstract available

  8. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    PubMed         Abstract available

  9. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    PubMed         Abstract available

  10. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    PubMed         Abstract available

  11. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    PubMed         Abstract available

  12. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    PubMed         Abstract available

  13. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
    PubMed        

  14. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    PubMed         Abstract available

  15. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
    PubMed        

  16. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    PubMed         Abstract available

  17. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    PubMed        

  18. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed         Abstract available

  19. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed         Abstract available

  20. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    PubMed         Abstract available

  21. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed         Abstract available

  22. LEE JH, Lee HS, Cho AR, Lee YJ, et al
    Relationship between muscle mass index and LDL cholesterol target levels: Analysis of two studies of the Korean population.
    Atherosclerosis. 2021;325:1-7.
    PubMed         Abstract available

  23. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    PubMed        

  24. ZAFEIROPOULOS S, Farmakis I, Kartas A, Arvanitaki A, et al
    Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
    Atherosclerosis. 2021;323:37-43.
    PubMed         Abstract available

  25. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed         Abstract available

  26. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed         Abstract available

  27. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed         Abstract available

  28. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed         Abstract available

  29. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed         Abstract available

  30. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed         Abstract available

  31. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed         Abstract available

  32. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed         Abstract available

  33. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed         Abstract available


    Curr Opin Lipidol

  34. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    PubMed         Abstract available

  35. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    PubMed         Abstract available

  36. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    PubMed         Abstract available


    Metabolism

  37. PICHE ME, Clavel MA, Auclair A, Rodriguez-Flores M, et al
    Early benefits of bariatric surgery on subclinical cardiac function: Contribution of visceral fat mobilization.
    Metabolism. 2021;119:154773.
    PubMed         Abstract available

  38. XU X, Dong Y, Ma N, Kong W, et al
    MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.
    Metabolism. 2021 Mar 25:154768. doi: 10.1016/j.metabol.2021.154768.
    PubMed         Abstract available


    PLoS One

  39. EUSWAS N, Phonnopparat N, Morasert K, Thakhampaeng P, et al
    National trends in the prevalence of diabetic retinopathy among Thai patients with type 2 diabetes and its associated factors from 2014 to 2018.
    PLoS One. 2021;16:e0245801.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: